Last Updated: June 8, 2026

Claims for Patent: 10,301,390

✉ Email this page to a colleague

Summary for Patent: 10,301,390

Title:	Anti-IFNAR1 antibodies with reduced Fc ligand affinity
Abstract:	The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
Inventor(s):	Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
Assignee:	AstraZeneca AB , MedImmune LLC
Application Number:	US15/971,127

Details for Patent 10,301,390

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	July 13, 2017	⤷ Start Trial	2038-05-04
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	January 29, 2019	⤷ Start Trial	2038-05-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,301,390

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2009212273	⤷ Start Trial
Brazil	122020023189	⤷ Start Trial
Brazil	PI0907735	⤷ Start Trial
Canada	2713981	⤷ Start Trial
China	101952454	⤷ Start Trial
Cyprus	1117827	⤷ Start Trial
Denmark	2250279	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.